Evidence map›Paper›PMID 27232285›Full record

ReviewAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2017

Alarmins and Their Receptors as Modulators and Indicators of Alloimmune Responses.

B M Matta, D K Reichenbach, B R Blazar, H R Turnquist

Abstract readReview
In one paragraph

Review in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Trial
  2. M1 macrophage inhibits ferroptosis inFrontiers in cell and developmental biology · 2025
    Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Macrophage-inducible C-type lectin activates B cells to promote T cell reconstitution in heart allograft recipients.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022
    Article
  8. Revisiting Regulated Cell Death Responses in Viral Infections.International journal of molecular sciences · 2022
    Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Pleiotropic Effects of IL-33 on CD4Frontiers in immunology · 2019
    Review
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

B M MattaThomas E. Starzl Transplantation Institute and Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA.
D K ReichenbachDivision of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN.
B R BlazarDivision of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN.
H R TurnquistThomas E. Starzl Transplantation Institute and Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA.

Funding

TRAINING IN HEMOGLOBIN &CELL MEMBRANE RESEARCHT32HL007062 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller, Gregory M Vercellotti · 1985 to 2026
$10.3M
Enhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7M
IN VIVO PREVENTION OF MURINE GVHDR01AI034495 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1993 to 2016
$6.2M
T-CELL TARGETING FOR GVHDR01HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1995 to 2022
$5.4M
GVL TO REDUCE AML RELAPSE AFTER MURINE ALLOGENEIC BMTR01CA072669 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1997 to 2017
$4.9M
Immunoregulatory Mechanisms of IL-33 in Heart TransplantationR01HL122489 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Heth R Turnquist · 2015 to 2026
$4.9M
Interdisciplinary Training in Transplantation BiologyT32AI074490 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Angus W Thomson · 2007 to 2026
$4.2M
Countering the pro-inflammatory attributes of IL-33 during hematopoietic cell transplantation for tolerance inductionR21AI121981 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TURNQUIST, HETH R · 2016 to 2017
$418k
NCI NIH HHS R01 CA072669NHLBI NIH HHS R01 HL056067NHLBI NIH HHS R01 HL118979NHLBI NIH HHS R01 HL122489NHLBI NIH HHS T32 HL007062NIAID NIH HHS R01 AI034495NIAID NIH HHS R21 AI121981NIAID NIH HHS T32 AI074490
6 · The paper itself

Abstract

Cell damage and death releases alarmins, self-derived immunomodulatory molecules that recruit and activate the immune system. Unfortunately, numerous processes critical to the transplantation of allogeneic materials result in the destruction of donor and recipient cells and may trigger alarmin release. Alarmins, often described as damage-associated molecular patterns, together with exogenous pathogen-associated molecular patterns, are potent orchestrators of immune responses; however, the precise role that alarmins play in alloimmune responses remains relatively undefined. We examined evolving concepts regarding how alarmins affect solid organ and allogeneic hematopoietic cell transplantation outcomes and the mechanisms by which self molecules are released. We describe how, once released, alarmins may act alone or in conjunction with nonself materials to contribute to cytokine networks controlling alloimmune responses and their intensity. It is becoming recognized that this class of molecules has pleotropic functions, and certain alarmins can promote both inflammatory and regulatory responses in transplant models. Emerging evidence indicates that alarmins and their receptors may be promising transplantation biomarkers. Developing the therapeutic ability to support alarmin regulatory mechanisms and the predictive value of alarmin pathway biomarkers for early intervention may provide opportunities to benefit graft recipients.

Indexed as

AlarminsAnimalsGraft vs Host DiseaseHumansReceptors, ImmunologicTransplantation, HomologousAlarminsReceptors, Immunologicbasic (laboratory) research/sciencebiomarkerbone marrow/hematopoietic stem cell transplantationcytokines/cytokine receptorsgraft-versus-host disease (GVHD)heart transplantation/cardiologyimmunobiologyinnate immunitytranslational research/science

Identifiers

PMID27232285
PMCPMC5124552

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.